Clinical Trials

LymphoidOther hematologic neoplasm

32 enrolled

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04049539 2026-04-08

Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

28 enrolled

Leukemia, Myeloid, Acute

NCT04282187 2026-03-16

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

25 enrolled

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT05627232 2026-03-12

Tazemetostat and Palbociclib With CPX-351for R/R AML

Phase 1 Recruiting

24 enrolled

Leukemia, Myeloid, Acute

NCT03226418 2026-03-10

Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia

75 enrolled 14 charts

Leukemia, Myeloid, Acute

NCT03404193 2026-03-10

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

Phase 2 Terminated

235 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03969446 2026-03-05

Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

Phase 1 Recruiting

54 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02286726 2026-03-04

CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia

56 enrolled 11 charts

Leukemia, Myeloid, Acute

NCT03358719 2026-02-27

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Classical hematologyMyeloidOther hematologic neoplasm

8 enrolled 9 charts

Anemia, Refractory, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03629171 2026-02-20

Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

52 enrolled

Leukemia, Myeloid, Acute

NCT03672539 2026-02-20

Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

50 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04915612 2026-02-20

Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia

1 enrolled

Leukemia, Myeloid, Acute

NCT05906914 2026-02-04

CHA

65 enrolled

Classical hematologyOther hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07347171 2026-01-16

A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies

Phase 1 Recruiting

45 enrolled

Anemia, Refractory, with Excess of Blasts, Leukemia, Leukemia, Myeloid, Acute

NCT03661307 2026-01-12

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

73 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04128748 2025-12-17

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

52 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05564650 2025-12-08

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

6 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT04493164 2025-11-21

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

30 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT04188405 2025-11-20

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

20 enrolled

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Acute

NCT04707300 2025-11-20

HTLP-ONCO

10 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual, Hematologic Neoplasms

NCT06928662 2025-11-06

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

36 enrolled

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04195945 2025-07-10

CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients

60 enrolled

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute

NCT03009240 2025-06-17

Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia

30 enrolled

Leukemia, Myeloid, Acute

NCT02257138 2025-06-08

Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia

Phase 1/2 Completed

30 enrolled 14 charts

Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

NCT05222984 2025-05-30

Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax

17 enrolled

Leukemia, Myeloid, Acute

NCT06572631 2025-05-25

Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor

Phase 1 Withdrawn

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03063944 2025-05-15

STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy

37 enrolled

Phase EARLY_PHASE1 Completed

Leukemia, Myeloid, Acute

NCT04628338 2025-04-29

IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

8 enrolled

Phase 3 Active not recruiting

Graft vs Host Disease, Leukemia, Myeloid, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05177731 2024-10-03

Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML

188 enrolled

Leukemia, Myeloid, Acute

NCT04905810 2024-05-29

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

20 enrolled

Leukemia, Myeloid, Acute

NCT04526288 2024-05-23

CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease

Phase 2 Terminated

1 enrolled 6 charts

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute

NCT06046313 2024-03-05

Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS

120 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03904251 2023-11-18

CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia

Phase 1 Terminated

13 enrolled

Leukemia, Leukemia, Myeloid, Acute

NCT03825796 2023-09-28

CPX-351 Plus Enasidenib for Relapsed AML

2 enrolled

Leukemia, Myeloid, Acute

NCT05188326 2023-06-08

Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly Patients

Phase 3 Completed

54 enrolled

Leukemia, Myeloid, Acute

NCT04146038 2023-05-24

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

5 enrolled 9 charts

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT01834248 2022-07-22

DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

9 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04655391 2022-06-09

Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation

Phase 1 Withdrawn

Leukemia, Myeloid, Acute

NCT04493099 2020-11-12

Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML

Phase 1/2 Withdrawn

Leukemia, Myeloid, Acute

NCT02921061 2020-03-17

Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS

Phase 1/2 Completed

28 enrolled 13 charts

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT02129101 2019-10-30

Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies

63 enrolled